Navigation Links
Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
Date:12/18/2007

WAYNE, Pa., Dec. 18 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq Capital Market: ESMC) today announced that its Drew Scientific subsidiary received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the D3 Hematology System, an automatic three-part differential Hematology Analyzer. Drew Scientific plans to commence shipments of the product in the United States by month-end.

"The FDA clearance represents a major step for Drew, as it now provides two upgraded instruments for sale in fiscal 2008 along with the TRILOGY Analyzer that was approved in July," said Frank Matuszak, Drew's Vice President of Sales and Marketing. "For the past twelve months, we have successfully distributed the D3 System outside of the United States. We expect that the D3 will be equally well received in the U.S. marketplace."

The D3 Hematology System adds to the Company's wide range of top quality and leading edge hematology systems. This flexible and easy-to-use instrument offers simple installation, low maintenance and immediate user acceptance and productivity. The D3 incorporates advanced technology for superior reliability of 3-part differential blood analysis. Features include:
-- Low reagent consumption and very small sample size to minimize

laboratory waste.

-- Advanced user flexibility with easy-to-use built-in color touch screen,

providing on screen histograms and storage of up to 500 records and QC

statistics.

-- Easy installation and user interface with multi-language capability.

For additional information on the D3 Hematology System, please visit the Drew Scientific web site at http://www.drew-scientific.com.

Doug Nickols, President of Drew Scientific, commented, "FDA clearance is another important step in the continued development of the D3 Hematology System. With this advancement and continued growing interest in the D3 System abroad, we expect to accelerate the pace of our analyzer placements worldwide."

Drew Scientific is a diagnostics company specializing in the design, manufacture and distribution of instruments for blood cell counting and blood analysis. Drew Scientific is focused on providing instrumentation and consumables for the physician office and veterinary office laboratories. Drew Scientific also supplies the reagent and other consumable materials needed to operate the instruments.

Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. Escalon seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities, although any such partnerships or acquisitions may not occur. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Waterbury, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. They are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to
-- implement its growth and marketing strategies, improve upon the

operations of the Company's business units, including the integration

of Drew's and MRP's operations, the reorganization of the Drew business

and the integration of any acquisitions it may undertake, if any, of

which there can be no assurance,

-- implement cost reductions,

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions. Other factors include uncertainties and risks related to

-- new product development, commercialization, manufacturing and market

acceptance of new products,

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

Escalon or third parties,

-- introduction of competitive products,

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10-K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Escalon(R) Reports Financial Results for 2007 Fiscal Year
2. Escalon(R) Reports First Quarter Fiscal 2008 Results
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... , ... Five consumer packaged goods (CPG) products were selected by the SupplySide ... Nopavera Plus was named to the short list in the Specialty Supplements category. ... presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in ...
(Date:9/20/2017)... ... 2017 , ... “The Trials I Face to Receive God’s Grace”: a ... aspirations and goals to better one’s life through God. “The Trials I Face to ... all the wrong places, found a love for writing. Green feels that expressing his ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of ... more than $15,000 in just a couple of weeks for those affected by ... world-class instructor seminars, organizers expect to double those initial funds with the “Submit ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: